Virios Therapeutics Inc Stock
Virios Therapeutics Inc Stock price
Key metrics
| Market capitalization | $9.40m |
| Enterprise Value | $7.36m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 5.75 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-5.82m |
| Free Cash Flow (TTM) Free Cash Flow | $-4.13m |
| Cash position | $2.04m |
Is Virios Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
Virios Therapeutics Inc Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Virios Therapeutics Inc:
Analyst Opinions
1 Analyst has issued a forecast Virios Therapeutics Inc:
Financial data from Virios Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -5.82 -5.82 |
9%
9%
|
EBIT (Operating Income) EBIT | -5.82 -5.82 |
9%
9%
|
| Net Profit | -5.73 -5.73 |
8%
8%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Virios Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Virios Therapeutics Inc Stock News
Company Profile
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
| Head office | United States |
| CEO | Gregory Duncan |
| Founded | 2012 |
| Website | www.dwtx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
